Early research (Phase 1)Study completedNCT03600155
What this trial is testing
Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome
Who this might be right for
Allogeneic Hematopoietic Stem Cell Transplantation RecipientMyelodysplastic SyndromeRecurrent Acute Myeloid Leukemia+1 more
M.D. Anderson Cancer Center 29